MedTrace Logo

Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia

NCT05002699 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-05-17

No results posted yet for this study

Summary

The 'Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia' (IMPACT-AD BC) study is an observational, longitudinal cohort study that will examine the impact of cerebrospinal fluid (CSF) testing for core Alzheimer's disease biomarkers on clinical decision making, diagnosis and health system utilization. In addition to data collection from physicians, the study will engage patients and their care partners in assessing the value of biomarker testing. IMPACT-AD BC investigators hypothesize that testing for CSF biomarkers of Alzheimer's disease in individuals with cognitive impairment, as part of routine clinical care, improves clinical management, diagnostic certainty, diagnostic accuracy, and healthcare resource utilization, and that patients and their care partners find the information valuable in planning for the future.

Conditions

Interventions

DIAGNOSTIC_TEST

Alzheimer's disease CSF biomarkers

Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.

Sponsors & Collaborators

  • Brain Canada

    collaborator OTHER

  • Health Canada

    collaborator OTHER_GOV

  • Michael Smith Foundation for Health Research

    collaborator OTHER

  • Women's Brain Health Initiative

    collaborator UNKNOWN

  • St. Paul's Foundation

    collaborator UNKNOWN

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Mari L. DeMarco, PhD · University of British Columbia

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2022-08-31
Completion
2023-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05002699 on ClinicalTrials.gov